Skip to Content

Efficacy of trastuzumab-deruxtecan therapy in HER2-positive breast cancer

When treating a patient with breast cancer and brain metastases the primary goal is maintaining the quality of life and neurocognitive function. This was also the goal of the TUXEDO-1 study – a prospective, open-label, single-arm phase II trial. This study enrolled HER2-positive breast cancer patients with newly diagnosed brain metastases (BM) or progressive BM with no immediate need for local therapy.

In this MEDtalk from ESMO 2022, Angelika Starzer, MD, Medical University of Vienna, Austria, presents the main results of the study.

Angelika Starzer

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top